| Index | S&P 500, NDX | P/E | 19.91 | EPS (ttm) | 40.43 | Insider Own | 1.69% | Shs Outstand | 102.95M | Perf Week | 1.81% |
| Market Cap | 82.88B | Forward P/E | 12.69 | EPS next Y | 63.43 | Insider Trans | -0.48% | Shs Float | 99.07M | Perf Month | 1.13% |
| Enterprise Value | 76.87B | PEG | 2.56 | EPS next Q | - | Inst Own | 65.25% | Short Float | 2.17% | Perf Quarter | 20.66% |
| Income | 4.33B | P/S | 5.34 | EPS this Y | 37.06% | Inst Trans | 0.00% | Short Ratio | 2.87 | Perf Half Y | 7.11% |
| Sales | 15.53B | P/B | 2.61 | EPS next Y | 6.44% | ROA | 10.37% | Short Interest | 2.15M | Perf YTD | 4.29% |
| Book/sh | 308.01 | P/C | 10.37 | EPS next 5Y | 7.77% | ROE | 13.81% | 52W High | 859.33 -6.32% | Perf Year | 37.67% |
| Cash/sh | 77.66 | P/FCF | 23.53 | EPS past 3/5Y | 2.77% 6.33% | ROIC | 9.19% | 52W Low | 572.76 40.55% | Perf 3Y | -2.54% |
| Dividend Est. | 3.76 (0.47%) | EV/EBITDA | 13.37 | Sales past 3/5Y | 5.62% 11.04% | Gross Margin | 84.86% | Volatility | 2.36% 2.70% | Perf 5Y | 45.51% |
| Dividend TTM | 3.70 (0.46%) | EV/Sales | 4.95 | EPS Y/Y TTM | 5.45% | Oper. Margin | 25.56% | ATR (14) | 21.32 | Perf 10Y | 114.22% |
| Dividend Ex-Date | Aug 18, 2026 | Quick Ratio | 2.78 | Sales Y/Y TTM | 9.38% | Profit Margin | 27.86% | RSI (14) | 58.04 | Recom | 2.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.34 | EPS Q/Q | 10.86% | SMA20 | 5.06% | Beta | 0.13 | Target Price | 856.80 |
| Payout | 8.74% | Debt/Eq | 0.09 | Sales Q/Q | 16.73% | SMA50 | 1.72% | Rel Volume | 0.72 | Prev Close | 819.09 |
| Employees | 15,410 | LT Debt/Eq | 0.09 | Earnings | Oct 30 | SMA200 | 9.38% | Avg Volume | 732.94K | Price | 805.02 |
| IPO Date | Apr 02, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 40.69% 12.40% | Net Debt/EBITDA | -0.08 | Volume | 525,558 | Change | -1.72% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | Piper Sandler | Overweight | $854 → $865 |
| Oct-15-26 | Upgrade | UBS | Neutral → Buy | $978 |
| Oct-08-26 | Reiterated | Raymond James | Outperform | $910 → $911 |
| Oct-08-26 | Reiterated | RBC Capital | Sector Perform | $737 → $810 |
| Oct-07-26 | Reiterated | Morgan Stanley | Equal Weight | $758 → $779 |
| Oct-07-26 | Reiterated | Truist Securities | Buy | $769 → $780 |
| Oct-01-26 | Reiterated | BMO Capital | Outperform | $730 → $920 |
| Oct-01-26 | Reiterated | Jefferies | Buy | $930 |
| Oct-01-26 | Upgrade | Argus Research | Hold → Buy | $850 |
| Sep-10-26 | Reiterated | HSBC | Buy | $800 → $920 |
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15,534 | 14,343 | 14,202 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,353 | 2,101 | 1,971 | — | — | — | — | — | — | |
| Gross Profit | 13,183 | 12,242 | 12,232 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2,743 | 2,700 | 2,954 | — | — | — | — | — | — | |
| Research and Development | 6,461 | 5,850 | 5,233 | — | — | — | — | — | — | |
| Other Operating Expense | 9 | 114 | 54 | — | — | — | — | — | — | |
| Operating Income | 3,971 | 3,578 | 3,991 | — | — | — | — | — | — | |
| Interest Expense | 55 | 44 | 55 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1,251 | 1,697 | 844 | — | — | — | — | — | — | |
| Net Income Before Taxes | 5,166 | 5,231 | 4,780 | — | — | — | — | — | — | |
| Income Taxes | 837 | 726 | 367 | — | — | — | — | — | — | |
| Consolidated Net Income | 4,329 | 4,505 | 4,413 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 4,329 | 4,505 | 4,413 | — | — | — | — | — | — | |
| Net Income | 4,329 | 4,505 | 4,413 | — | — | — | — | — | — | |
| EPS (Recurring) | 41.88 | 43.07 | 40.90 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 41.88 | 43.07 | 40.90 | — | — | — | — | — | — | |
| EPS (Diluted) | 40.43 | 41.48 | 38.34 | — | — | — | — | — | — | |
| EBITDA | 5,750 | 5,818 | 5,318 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 19.91 | 18.61 | 18.58 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.34 | 5.65 | 5.42 | — | — | — | — | — | — | |
| Gross Margin | 84.87 | 85.35 | 86.13 | — | — | — | — | — | — | |
| Operating Margin | 25.56 | 24.95 | 28.10 | — | — | — | — | — | — | |
| Net Margin | 27.87 | 31.41 | 31.07 | — | — | — | — | — | — | |
| Shares Outstanding | 103 | 105 | 108 | — | — | — | — | — | — | |
| Market Capitalization | 82,917 | 81,046 | 76,932 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MURPHY ANDREW J | Co-Chief Scientific Officer | Oct 14 '26 | Sale | 772.70 | 4,147 | 3,204,377 | 47,833 | Oct 15 |
| MURPHY ANDREW J | Co-Chief Scientific Officer | Oct 13 '26 | Option Exercise | 381.92 | 17,000 | 6,492,640 | 64,833 | Oct 15 |
| McCourt Marion | EVP Commercial | Sep 03 '26 | Sale | 857.39 | 1,131 | 969,708 | 12,003 | Sep 03 |
| Guarini Kathryn | Director | Sep 02 '26 | Sale | 850.00 | 400 | 340,000 | 603 | Sep 03 |
| McCourt Marion | EVP Commercial | Sep 02 '26 | Sale | 850.00 | 1,215 | 1,032,750 | 13,134 | Sep 03 |
| Guarini Kathryn | Director | Sep 02 '26 | Option Exercise | 719.37 | 400 | 287,748 | 1,003 | Sep 03 |
| LAROSA JOSEPH J | EVP General Counsel and Secret | Aug 19 '26 | Option Exercise | 381.92 | 12,282 | 4,690,741 | 45,392 | Aug 21 |
| Fenimore Christopher R. | EVP Finance CFO | Aug 18 '26 | Option Exercise | 381.92 | 6,283 | 2,399,603 | 24,583 | Aug 20 |
| Guarini Kathryn | Director | Aug 10 '26 | Option Exercise | 719.37 | 400 | 287,748 | 1,003 | Aug 12 |
| Guarini Kathryn | Director | Aug 10 '26 | Sale | 800.00 | 400 | 320,000 | 603 | Aug 12 |
| Zoghbi Huda Y | Director | Aug 10 '26 | Option Exercise | 376.69 | 800 | 301,352 | 2,503 | Aug 12 |
| Zoghbi Huda Y | Director | Aug 10 '26 | Sale | 800.00 | 800 | 640,000 | 1,703 | Aug 12 |
| RYAN ARTHUR F | Director | Jul 02 '26 | Sale | 650.15 | 200 | 130,030 | 17,303 | Jul 07 |
| RYAN ARTHUR F | Director | May 01 '26 | Sale | 705.24 | 100 | 70,524 | 17,503 | May 04 |
| RYAN ARTHUR F | Director | Apr 01 '26 | Sale | 777.27 | 100 | 77,727 | 17,603 | Apr 03 |